

Emerging Treatment Options | Questions to Ask Your Doctor

- What are the new and developing treatment options?
- Will any of these be a fit for me now or in the future?
- Should I meet with a myeloma specialist to discuss my options?

Targets Expressed on Myeloma Cells

BCMA (B-cell maturation antigen)
 GPRC5D (G protein-coupled receptor 5D)
 FcRH5 (Fc receptor-homolog 5)

CAR T-Cell Therapies for Myeloma

- Idecabtagene Vicleucel (Abecma) or Ide-cel
- Ciltacabtagene Autoleucel (Carvykti) or Cilta-cel

Bispecific Antibodies for Myeloma

- Teclistamab (Tecvayli)
- Elranatamab (Elrexfio)
- Talquetamab (Talvey)

Next-Generation Myeloma Agents: CELMoD Drugs

CELMoDs (Cereblon E3 Ligase Modulatory Drugs): Designed to attack myeloma, not only killing myeloma cells directly but also by engaging other immune cells. CELMoDs in development include: iberdomide and mezigdomide.

Glossary

Bispecific Antibodies (Bispecific T-cell engagers or BiTEs): Class of bispecific monoclonal antibodies that harness the power of the immune system to treat myeloma by binding to two different antigens at the same time.

CAR (Chimeric Antigen Receptor) T-Cell Therapy: Treatment in which the T cells (a type of immune system cell) of a patient are laboratory-altered to attack cancer cells in the body.

GMMG-CONCEPT Trial: Clinical Phase II, Multicenter, Open-label Study Evaluating Induction, Consolidation and Maintenance With Isatuximab (SAR650984), Carfilzomib, Lenalidomide and Dexamethasone (I-KRd) in Primary Diagnosed High-risk Multiple Myeloma patients.

Standard of Care: An established guideline that is consensus among experts as the most appropriate and/or effective treatment for a specific type and stage of cancer.

Perseus Trial: Phase III Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for Autologous Stem Cell Transplantation (ASCT).



Evolve Myeloma is brought to you by the Patient Empowerment Network. Funding is provided by a sponsorship from Bristol Myers Squibb, Merck, and through generous donations from people like you.



question@powerfulpatients.org

www.powerfulpatients.org



[@power4patients](https://twitter.com/power4patients)